BRPI0518647A2 - processo para a produÇço de um composto, e, composto - Google Patents

processo para a produÇço de um composto, e, composto

Info

Publication number
BRPI0518647A2
BRPI0518647A2 BRPI0518647-1A BRPI0518647A BRPI0518647A2 BR PI0518647 A2 BRPI0518647 A2 BR PI0518647A2 BR PI0518647 A BRPI0518647 A BR PI0518647A BR PI0518647 A2 BRPI0518647 A2 BR PI0518647A2
Authority
BR
Brazil
Prior art keywords
compound
production
intermediates
processes
producing
Prior art date
Application number
BRPI0518647-1A
Other languages
English (en)
Inventor
Michael Butters
Steven Robert Lenger
Paul Michael Murray
Evan William Snape
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518647(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of BRPI0518647A2 publication Critical patent/BRPI0518647A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

PROCESSO PARA A PRODUÇçO DE UM COMPOSTO, E, COMPOSTO. É descrito um processo para a formação de um composto da fórmula (I) ou um sal farmaceuticamente aceitável do mesmo através de uma reação Heck. São também descritos intermediários úteis no processo e processos para a produção dos referidos intermediários.
BRPI0518647-1A 2004-12-24 2005-12-22 processo para a produÇço de um composto, e, composto BRPI0518647A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428328.9A GB0428328D0 (en) 2004-12-24 2004-12-24 Chemical process
PCT/GB2005/004999 WO2006067456A2 (en) 2004-12-24 2005-12-22 Process for preparing rosuvastatin

Publications (1)

Publication Number Publication Date
BRPI0518647A2 true BRPI0518647A2 (pt) 2008-12-02

Family

ID=34130901

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518647-1A BRPI0518647A2 (pt) 2004-12-24 2005-12-22 processo para a produÇço de um composto, e, composto

Country Status (15)

Country Link
US (1) US8034932B2 (pt)
EP (2) EP2361906A1 (pt)
JP (1) JP5127460B2 (pt)
KR (1) KR20070092307A (pt)
CN (1) CN101084197B (pt)
AU (1) AU2005317880B2 (pt)
BR (1) BRPI0518647A2 (pt)
CA (1) CA2589775A1 (pt)
GB (1) GB0428328D0 (pt)
IL (1) IL183528A (pt)
MX (1) MX2007007777A (pt)
NO (1) NO20072872L (pt)
NZ (1) NZ555769A (pt)
WO (1) WO2006067456A2 (pt)
ZA (1) ZA200704535B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
MXPA04000322A (es) 2001-07-13 2005-09-08 Astrazeneca Uk Ltd Preparacion de compuestos de aminopirimidina.
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
KR101060215B1 (ko) 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US7612203B2 (en) 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
EP1948618A1 (en) * 2006-09-18 2008-07-30 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
EP1978020A1 (en) * 2007-04-03 2008-10-08 LEK Pharmaceuticals D.D. Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof
WO2008119810A2 (en) 2007-04-03 2008-10-09 Lek Pharmaceuticals D.D. Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof
CA2696195A1 (en) * 2007-08-20 2009-02-26 Ratiopharm Gmbh Process for preparing pyrimidine derivatives
EA201000214A1 (ru) 2007-08-28 2010-10-29 Рациофарм Гмбх Способ получения производных пентадикарбоновой кислоты
US20110245285A1 (en) * 2008-09-09 2011-10-06 Biocon Limited Process for preparation of rosuvastatin acetonide calcium
CN105669561B (zh) * 2014-11-19 2018-11-27 南京博优康远生物医药科技有限公司 一种4-(4-氟苯基)-5-烷氧基羰基-6-异丙基-3,4-二氢嘧啶-2(1h)-酮的制备方法
HUE069744T2 (hu) * 2015-01-23 2025-04-28 Centrient Pharmaceuticals Netherlands B V Fejlesztett eljárás a sztatin prekurzor elõállítására
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US480621A (en) 1892-08-09 Oiler for handsaws
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
US4625039A (en) 1983-12-21 1986-11-25 Sandoz Pharm. Corp. 4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates
US4650890A (en) 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4677211A (en) 1984-06-29 1987-06-30 Sandoz Pharmaceuticals Corp. Preparation of lactones
US4957971A (en) 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4808621A (en) * 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5102893A (en) 1986-07-07 1992-04-07 Warner-Lambert Company Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3739882A1 (de) 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
DE3741508A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Wasserloesliche disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
GB2244706B (en) 1988-02-18 1992-07-15 Bristol Myers Co Preparation of antihypercholesterolemic tetrazole intermediates
AU3214689A (en) * 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
ES2106926T3 (es) 1992-07-02 1997-11-16 Hoechst Ag Procedimiento para la preparacion del ester terc-butilico del acido (3r,5s)6-hidroxi-3,5-o-isopropiliden-3,5-dihidroxi-hexanoico.
JP3197971B2 (ja) 1993-03-01 2001-08-13 塩野義製薬株式会社 ５−カルボアルコキシピリミジン誘導体の合成方法
MX9703518A (es) 1994-11-16 1997-08-30 Synaptic Pharma Corp Dihidropirimidinas y usos de las mismas.
DE19517186A1 (de) 1995-05-11 1996-11-14 Bayer Ag Verfahren zur Herstellung substituierter 2-Fluor-pyrimidine
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
WO1997021687A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Process for making dihydropyrimidinones
US6387369B1 (en) * 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
CA2297889A1 (en) 1997-08-05 1999-02-18 Norihiro Ikemoto Alpha 1a adrenergic receptor antagonist
CN1122029C (zh) 1998-12-10 2003-09-24 钟渊化学工业株式会社 制备辛伐他汀的方法
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
JP4204132B2 (ja) 1999-02-19 2009-01-07 大塚化学ホールディングス株式会社 摩擦材
WO2000078730A1 (en) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
WO2001004336A1 (de) 1999-07-09 2001-01-18 Forschungszentrum Jülich GmbH Verfahren zur reduktion von keto-carbonsäuren und deren estern
US6579984B1 (en) 1999-07-13 2003-06-17 Lonza Ag Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) * 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
US8374574B1 (en) 2000-07-06 2013-02-12 Motorola Mobility Llc Method and apparatus for storing a message for playback during a user-initiated emergency telephone call from a wireless device
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
CN1473156A (zh) * 2000-11-10 2004-02-04 - 嘧啶衍生物及其作为神经肽y受体配体的用途
CZ20033329A3 (cs) 2001-06-06 2004-11-10 Bristol-Myers Squibb Company Způsob přípravy chirálních sulfondiolů a dihydroxykyselin inhibitorů HMG CoA reduktázy
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
HUP0401145A3 (en) 2001-07-06 2008-08-28 Ciba Sc Holding Ag Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
MXPA04000322A (es) 2001-07-13 2005-09-08 Astrazeneca Uk Ltd Preparacion de compuestos de aminopirimidina.
JP2005503393A (ja) 2001-08-22 2005-02-03 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド インドール誘導体の製造方法
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DK1578733T3 (da) 2002-12-10 2011-06-14 Ranbaxy Lab Ltd Fremgangsmåde til fremstilling af rosuvastatin
KR101060215B1 (ko) 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
CA2550742A1 (en) 2003-12-24 2005-07-14 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
MX2007007777A (es) 2007-08-14
IL183528A (en) 2012-02-29
JP2008525407A (ja) 2008-07-17
EP1871747A2 (en) 2008-01-02
CN101084197A (zh) 2007-12-05
JP5127460B2 (ja) 2013-01-23
NZ555769A (en) 2010-01-29
EP2361906A1 (en) 2011-08-31
WO2006067456A3 (en) 2006-09-21
CN101084197B (zh) 2012-06-13
US20080207903A1 (en) 2008-08-28
AU2005317880A1 (en) 2006-06-29
KR20070092307A (ko) 2007-09-12
WO2006067456A2 (en) 2006-06-29
ZA200704535B (en) 2008-11-26
AU2005317880B2 (en) 2009-05-28
US8034932B2 (en) 2011-10-11
GB0428328D0 (en) 2005-02-02
IL183528A0 (en) 2007-09-20
CA2589775A1 (en) 2006-06-29
NO20072872L (no) 2007-09-17

Similar Documents

Publication Publication Date Title
BRPI0518647A2 (pt) processo para a produÇço de um composto, e, composto
BRPI0318811B8 (pt) derivados de ciclohexanol espirocíclicos
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
BRPI0516735B8 (pt) métodos para produção de (r)-2-acetamido-n-benzil-3-metoxipropionamida (lacosamida) e de uma formulação farmacêutica, e uso de (r)-n-benzil-2-nboc-amino-3-metoxipropionamida (c-937)
CR8975A (es) Proceso para la produccion de derivados de amina opticamente activos
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
ATE539054T1 (de) Verfahren zur herstellung von dihydropyrrolderivaten als zwischenprodukte
EA200802074A1 (ru) Способ получения бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ для лечения или профилактики ретровирусных инфекций с ее помощью и способ ингибирования вич протеазы с ее помощью
CY1112520T1 (el) Βενζυλαμινες, μια διαδικασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδεις παραγοντες
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
BR112012017845A2 (pt) novo processo para produção de derivados de benzofenona
CY1108156T1 (el) Στερεοεκλεκτικη συνθεση αναλογων βιταμινης d
ATE483679T1 (de) Substituierte cyclohexylessigsäure-derivate
BR0312593A (pt) Aciluréias substituìdas por uréia e uretano, processo para a sua produção e sua aplicação
TW200716582A (en) Process for making a pharmaceutical compound
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
ATE466003T1 (de) Herstellung von 2-aminothiazol-5- carbonsäurederivaten
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
CO5690587A2 (es) Derivados de acido bensoilureidopiridil-piperidin-y pirrolidin carboxilico sustituido, metodo para su produccion y su uso
BR0313210A (pt) Processos microbiológicos para a produção de 11alfa-hidróxi esteróides 7alfa-substituìdos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.